Cystic Fibrosis (cf) Therapeutics Market By Drug Class, And Route Of Administration- Global Industry Analysis And Forecast To 2023
Published On : February 2018 Pages : 111 Category: Pharmaceuticals Report Code : CM03642
Industry Outlook and Trend Analysis
The Cystic Fibrosis (CF) Therapeutics Market was worth USD 2.15 billion in 2017 and is expected to reach approximately USD 22.46 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 29.79% during the forecast period. Expanding commonness of Cystic Fibrosis (CF) combined with rising rate of treatment is one of the key variables expected to push the interest for these therapeutics over the figure time frame. In addition, increment in R&D subsidizing by both private and open associations, rising number of activities attempted by philanthropic associations, and existence of ideal reimbursement policies are a portion of the essential elements anticipated that would drive the market in the coming few years. Moreover, expanding number of clinical trials to extend its objective patient base with the current medication portfolio is likewise among a portion of the drivers of this market.
Drug Class Outlook and Trend Analysis
On the basis of drug class, the market is sectioned into pancreatic enzyme supplements, bronchodilators, mucolytics, and CFTR modulators. The main factor in the treatment of CF is keeping up the function of the lung while controlling respiratory infection and clearing airways routes of mucus, dealing with the wholesome treatment, and controlling the complications. In 2017, CFTR modulators represented the biggest revenue with a share of roughly 47.3% inferable from the launch of new drug Orkambi. This drug is in charge of adjusting the capacity of defective protein caused by the CF gene.
Route of Administration Outlook and Trend Analysis
On the basis of route of administration, the market is sectioned into inhaled route and oral drugs. Oral route represented the biggest share of almost 63.7% out of 2017 inferable from the favourable circumstances related with its organization, for example, accommodation and simplicity of usage without the assistance of a medicinal services proficient.
Regional Outlook and Trend Analysis
Geographically, the market is portioned into Europe, North America, Asia Pacific, Latin America, and Middle East and Africa. North America represented the biggest income of USD 2,396.4 million in 2017. CF is most pervasive in North America as a large portion of the general population influenced with CF is of Caucasian plunge. Nonetheless, Asia Pacific is foreseen to be the quickest developing fragment.
Competitive Insights
The leading players in the market are Teva Pharmaceutical Industries, Merck & Co, AbbVie Inc, Alcresta Therapeutics Inc, Vertex Pharmaceuticals, ALAXIA, Gilead Sciences, Allergan, Roche Holding AG, AstraZeneca and Novartis. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
The Cystic Fibrosis (CF) Therapeutics Market is segmented as follows-
By Drug Class:
- Pancreatic enzyme supplements
- Bronchodilators
- CFTR modulators
- Mucolytics
By Route of Administration:
- Inhaled drugs
- Oral drugs
By Region
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- United Arab Emirates
- Others
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2023?
- What will be the industry market growth from 2017 to 2023?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Cystic Fibrosis Therapeutics Market, By Drug Class, Estimates and Forecast, 2014-2023 ($Million)
· Pancreatic enzyme supplements
· Bronchodilators
· CFTR modulators
· Mucolytics
· Cystic Fibrosis Therapeutics Market, By Route of Administration, Estimates and Forecast, 2014-2023 ($Million)
· Inhaled drugs
· Oral drugs
· Cystic Fibrosis Therapeutics Market, By Region, Estimates and Forecast, 2014-2023 ($Million)
· North America
§ North America Cystic Fibrosis Therapeutics Market, By Country
§ North America Cystic Fibrosis Therapeutics Market, By Drug Class
§ North America Cystic Fibrosis Therapeutics Market, By Route of Administration
o U.S. Cystic Fibrosis Therapeutics Market, By Drug Class
o U.S. Cystic Fibrosis Therapeutics Market, By Route of Administration
o Canada Cystic Fibrosis Therapeutics Market, By Drug Class
o Canada Cystic Fibrosis Therapeutics Market, By Route of Administration
o Mexico Cystic Fibrosis Therapeutics Market, By Drug Class
o Mexico Cystic Fibrosis Therapeutics Market, By Route of Administration
· Europe
§ Europe Cystic Fibrosis Therapeutics Market, By Country
§ Europe Cystic Fibrosis Therapeutics Market, By Drug Class
§ Europe Cystic Fibrosis Therapeutics Market, By Route of Administration
o Germany Cystic Fibrosis Therapeutics Market, By Drug Class
o Germany Cystic Fibrosis Therapeutics Market, By Route of Administration
o France Cystic Fibrosis Therapeutics Market, By Drug Class
o France Cystic Fibrosis Therapeutics Market, By Route of Administration
o UK Cystic Fibrosis Therapeutics Market, By Drug Class
o UK Cystic Fibrosis Therapeutics Market, By Route of Administration
o Italy Cystic Fibrosis Therapeutics Market, By Drug Class
o Italy Cystic Fibrosis Therapeutics Market, By Route of Administration
o Spain Cystic Fibrosis Therapeutics Market, By Drug Class
o Spain Cystic Fibrosis Therapeutics Market, By Route of Administration
o Rest of Europe Cystic Fibrosis Therapeutics Market, By Drug Class
o Rest of Europe Cystic Fibrosis Therapeutics Market, By Route of Administration
· Asia-Pacific
§ Asia-Pacific Cystic Fibrosis Therapeutics Market, By Country
§ Asia-Pacific Cystic Fibrosis Therapeutics Market, By Drug Class
§ Asia-Pacific Cystic Fibrosis Therapeutics Market, By Route of Administration
o Japan Cystic Fibrosis Therapeutics Market, By Drug Class
o Japan Cystic Fibrosis Therapeutics Market, By Route of Administration
o Australia Cystic Fibrosis Therapeutics Market, By Drug Class
o Australia Cystic Fibrosis Therapeutics Market, By Route of Administration
o India Cystic Fibrosis Therapeutics Market, By Drug Class
o India Cystic Fibrosis Therapeutics Market, By Route of Administration
o South Korea Cystic Fibrosis Therapeutics Market, By Drug Class
o South Korea Cystic Fibrosis Therapeutics Market, By Route of Administration
o Rest of Asia-Pacific Cystic Fibrosis Therapeutics Market, By Drug Class
o Rest of Asia-Pacific Cystic Fibrosis Therapeutics Market, By Route of Administration
· Rest of the World
§ Rest of the World Cystic Fibrosis Therapeutics Market, By Country
§ Rest of the World Cystic Fibrosis Therapeutics Market, By Drug Class
§ Rest of the World Cystic Fibrosis Therapeutics Market, By Route of Administration
o Brazil Cystic Fibrosis Therapeutics Market, By Drug Class
o Brazil Cystic Fibrosis Therapeutics Market, By Route of Administration
o South Africa Cystic Fibrosis Therapeutics Market, By Drug Class
o South Africa Cystic Fibrosis Therapeutics Market, By Route of Administration
o Saudi Arabia Cystic Fibrosis Therapeutics Market, By Drug Class
o Saudi Arabia Cystic Fibrosis Therapeutics Market, By Route of Administration
o Turkey Cystic Fibrosis Therapeutics Market, By Drug Class
o Turkey Cystic Fibrosis Therapeutics Market, By Route of Administration
o United Arab Emirates Cystic Fibrosis Therapeutics Market, By Drug Class
o United Arab Emirates Cystic Fibrosis Therapeutics Market, By Route of Administration
o Others Cystic Fibrosis Therapeutics Market, By Drug Class
o Others Cystic Fibrosis Therapeutics Market, By Route of Administration
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Expanding commonness of Cystic Fibrosis
3.2.2. Restraints
3.2.2.1. High Pricing
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Cystic Fibrosis Therapeutics Market, By Drug Class
4.1. Introduction
4.2. Global Cystic Fibrosis Therapeutics Sales, Revenue and Market Share By Drug Class (2017-2017)
4.2.1. Global Cystic Fibrosis Therapeutics Sales and Sales Share By Drug Class (2017-2017)
4.2.2. Global Cystic Fibrosis Therapeutics Revenue and Revenue Share By Drug Class (2017-2017)
4.3. Cystic Fibrosis Therapeutics Market Assessment and Forecast, By Drug Class, 2017-2023
4.4. Pancreatic enzyme supplements
4.4.1. Market Assessment and Forecast, By Region, 2017-2023($Million)
4.5. Bronchodilators
4.5.1. Market Assessment and Forecast, By Region, 2017-2023($Million)
4.6. CFTR modulators
4.6.1. Market Assessment and Forecast, By Region, 2017-2023($Million)
4.7. Mucolytics
4.7.1. Market Assessment and Forecast, By Region, 2017-2023($Million)
5. Cystic Fibrosis Therapeutics Market, By Route of Administration
5.1. Introduction
5.2. Global Cystic Fibrosis Therapeutics Sales, Revenue and Market Share By Route of Administration (2017-2017)
5.2.1. Global Cystic Fibrosis Therapeutics Sales and Sales Share By Route of Administration (2017-2017)
5.2.2. Global Cystic Fibrosis Therapeutics Revenue and Revenue Share By Route of Administration (2017-2017)
5.3. The Cystic Fibrosis Therapeutics Market Assessment and Forecast, By Route of Administration, 2017-2023
5.4. Inhaled drugs
5.4.1. Market Assessment and Forecast, By Region, 2017-2023($Million)
5.5. Oral drugs
5.5.1. Market Assessment and Forecast, By Region, 2017-2023($Million)
6. Cystic Fibrosis Therapeutics Market, By Region
6.1. Introduction
6.2. Cystic Fibrosis Therapeutics Market Assessment and Forecast, By Region, 2017-2023 ($Million)
6.3. Global Cystic Fibrosis Therapeutics Sales, Revenue and Market Share by Regions
6.3.1. Global Cystic Fibrosis Therapeutics Sales by Regions (2017-2017)
6.3.2. Global Cystic Fibrosis Therapeutics Revenue by Regions (2017-2017)
6.4. North America
6.4.1. North America Cystic Fibrosis Therapeutics Sales and Growth Rate (2017-2017)
6.4.2. Market Assessment and Forecast, By Country, 2017-2023($Million)
6.4.3. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.4.4. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.4.5. U.S.
6.4.5.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.4.5.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.4.6. Canada
6.4.6.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.4.6.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.4.7. Mexico
6.4.7.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.4.7.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.5. Europe
6.5.1. Europe Cystic Fibrosis Therapeutics Sales and Growth Rate (2017-2017)
6.5.2. Market Assessment and Forecast, By Country, 2017-2023($Million)
6.5.3. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.5.4. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.5.5. Germany
6.5.5.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.5.5.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.5.6. France
6.5.6.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.5.6.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.5.7. UK
6.5.7.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.5.7.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.5.8. Italy
6.5.8.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.5.8.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.5.9. Spain
6.5.9.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.5.9.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.5.10. Rest of Europe
6.5.10.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.5.10.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.6. Asia-Pacific
6.6.1. Asia-Pacific Cystic Fibrosis Therapeutics Sales and Growth Rate (2017-2017)
6.6.2. Market Assessment and Forecast, By Country, 2017-2023($Million)
6.6.3. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.6.4. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.6.5. Japan
6.6.5.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.6.5.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.6.6. China
6.6.6.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.6.6.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.6.7. Australia
6.6.7.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.6.7.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.6.8. India
6.6.8.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.6.8.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.6.9. South Korea
6.6.9.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.6.9.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.6.10. Rest of Asia-Pacific
6.6.10.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.6.10.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.7. Rest of the World
6.7.1. Rest of the World Cystic Fibrosis Therapeutics Sales and Growth Rate (2017-2017)
6.7.2. Market Assessment and Forecast, By Country, 2017-2023($Million)
6.7.3. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.7.4. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.7.5. Brazil
6.7.5.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.7.5.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.7.6. Turkey
6.7.6.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.7.6.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.7.7. Saudi Arabia
6.7.7.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.7.7.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.7.8. South Africa
6.7.8.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.7.8.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.7.9. United Arab Emirates
6.7.9.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.7.9.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
6.7.10. Others
6.7.10.1. Market Assessment and Forecast, By Drug Class, 2017-2023($Million)
6.7.10.2. Market Assessment and Forecast, By Route of Administration, 2017-2023($Million)
7. Company Profiles
7.1. Teva Pharmaceutical Industries
7.1.1. Business Overview
7.1.2. Product Portfolio
7.1.3. Strategic Developments
7.1.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.2. Merck & Co
7.2.1. Business Overview
7.2.2. Product Portfolio
7.2.3. Strategic Developments
7.2.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.3. AbbVie Inc
7.3.1. Business Overview
7.3.2. Product Portfolio
7.3.3. Strategic Developments
7.3.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.4. Alcresta Therapeutics Inc
7.4.1. Business Overview
7.4.2. Product Portfolio
7.4.3. Strategic Developments
7.4.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.5. Vertex Pharmaceuticals
7.5.1. Business Overview
7.5.2. Product Portfolio
7.5.3. Strategic Developments
7.5.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.6. Allergan
7.6.1. Business Overview
7.6.2. Product Portfolio
7.6.3. Strategic Developments
7.6.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.7. Roche Holding AG
7.7.1. Business Overview
7.7.2. Product Portfolio
7.7.3. Strategic Developments
7.7.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.8. AstraZeneca
7.8.1. Business Overview
7.8.2. Product Portfolio
7.8.3. Strategic Developments
7.8.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.9. Novartis
7.9.1. Business Overview
7.9.2. Product Portfolio
7.9.3. Strategic Developments
7.9.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
8. Global Cystic Fibrosis Therapeutics Market Competition, by Manufacturer
8.1. Global Cystic Fibrosis Therapeutics Sales and Market Share by Manufacturer (2017-2017)
8.2. Global Cystic Fibrosis Therapeutics Revenue and Market Share by Manufacturer (2017-2017)
8.3. Top 5 Cystic Fibrosis Therapeutics Manufacturer Market Share
8.4. Market Competition Trend
List of Tables and Figures
*You can glance through the list of Tables and Figures when you view the sample copy of Cystic Fibrosis Therapeutics Market.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|